de Mello M F, Myczcowisk L M, Menezes P R
Service of Psychiatry and Medical Psychology, Hospital do Servidor Publico Estadual, São Paulo, Brazil.
J Psychother Pract Res. 2001 Spring;10(2):117-23.
The authors compared the outcomes of 35 outpatients with dysthymic disorder randomized to receive either treatment with moclobemide and interpersonal therapy (IPT) or moclobemide and routine clinical management. Diagnosis was based on the ICD-10 symptom checklist. Patients were evaluated by trained raters using the 17-item Hamilton Rating Scale for Depression (Ham-D), Montgomery-Asberg Depression Rating Scale (MADRS), Global Assessment of Functioning, and Quality of Life and Satisfaction Questionnaire at baseline, 12, 24, and 48 weeks. Patients in both treatment groups showed statistically significant improvement in all measures across time. There was a nonsignificant trend toward lower scores on Ham-D and MADRS for patients in the moclobemide plus IPT group. Longer, better-powered trials should be carried out to study the efficacy of IPT plus antidepressant medication in the treatment of dysthymic disorder.
作者比较了35例被随机分配接受吗氯贝胺与人际关系疗法（IPT）联合治疗或吗氯贝胺与常规临床管理的恶劣心境障碍门诊患者的治疗结果。诊断基于国际疾病分类第10版（ICD - 10）症状清单。在基线、12周、24周和48周时，由经过培训的评估者使用17项汉密尔顿抑郁评定量表（Ham - D）、蒙哥马利 - 阿斯伯格抑郁评定量表（MADRS）、功能总体评定量表以及生活质量与满意度问卷对患者进行评估。两个治疗组的患者在所有测量指标上随时间均显示出具有统计学意义的改善。吗氯贝胺加IPT组患者的Ham - D和MADRS得分有降低的趋势，但无统计学意义。应开展规模更大、效能更高的试验来研究IPT加抗抑郁药物治疗恶劣心境障碍的疗效。
